Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Sézary syndrome (SS) is an aggressive leukemia and a variant of cutaneous T-cell lymphomas (CTCL).
• Re-expression of the human Telomerase Reverse Transcriptase (hTERT) gene is observed in SS.
• Current treatments for SS offer limited long-term efficacy.

Purpose of the Study:

• To investigate the functional effects of epigenetic drugs on the clonogenic capacity of Sézary cells.
• To evaluate the impact of histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) on SS cell proliferation and tumor formation.

Main Methods:

• Utilized the soft agar assay to assess the clonogenic potential of Sézary cells.
• Analyzed the effects of HDAC inhibitors (romidepsin, vorinostat) and a DNMT inhibitor (5-azacytidine) on Sézary cells.
• Previously established that these epigenetic drugs downregulate hTERT expression without altering promoter methylation.

Main Results:

• Epigenetic drug treatment led to the downregulation of hTERT expression in Sézary cells.
• Treatment significantly reduced the proliferative capacity of Sézary cells in vitro.
• The tumor formation potential of Sézary cells was diminished under epigenetic drug pressure.

Conclusions:

• Epigenetic drugs demonstrate anti-proliferative and anti-tumorigenic effects on Sézary cells.
• Targeting hTERT expression with epigenetic therapies shows promise for treating Sézary syndrome.
• These findings suggest novel therapeutic avenues for managing this aggressive hematological malignancy.